Deanol and physostigmine in the treatment of L-dopa-induced dyskinesias.
Deanol and placebo were administered to 10 parkinsonian patients with levodopa-induced dyskinesias in a double-blind, crossover fashion. Deanol and placebo did not differ significantly in their effects on dyskinesias. The reported properties of deanol seem to be attributable to a placebo effect. There was no correlation with the results of the physostigmine test. Despite these disappointing results deanol remains intriguing, because in individual cases remarkable improvements on dyskinesias are reported.
D000368:Aged; D002986:Clinical Trials as Topic; D003642:Deanol / Q000627:therapeutic use*; D004311:Double-Blind Method; D004341:Drug Evaluation; D004409:Dyskinesia, Drug-Induced / Q000188:drug therapy*; D004983:Ethanolamines / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy; D010830:Physostigmine / Q000627:therapeutic use*; D010919:Placebos
D004983:Ethanolamines; D010919:Placebos; D003642:Deanol; D007980:Levodopa; D010830:Physostigmine